Prasco Laboratories

What Prasco Laboratories does

Prasco Laboratories is a privately held U.S. pharmaceutical company headquartered in Mason, Ohio, founded in 2002 and operating with 51–100 employees. The company specializes in the manufacture and distribution of authorized generic versions of branded prescription medications, operating under a model in which original brand owners license Prasco to produce therapeutically equivalent generics, typically after branded products are discontinued or as a lifecycle management tool. Its flagship commercial product is the authorized generic version of GSK's Flovent (albuterol sulfate metered dose inhaler), which Prasco has distributed in the United States since GSK discontinued its branded Flovent line at the start of 2024.

Prasco generates revenue through the sale of authorized generic pharmaceuticals to retail and institutional pharmacies, hospital networks, and healthcare providers, using existing pharmaceutical distribution channels. Its go-to-market is partnership-driven rather than direct-to-consumer: the company secures licensing arrangements with brand owners such as GSK, then routes product through established U.S. pharmacy wholesalers and provider networks. In December 2025, Prasco announced a strategic collaboration with Frontier Scientific Solutions to add temperature-controlled logistics capabilities, aimed at reducing damages, theft, and shortages as the portfolio expands.

The business carries structural concentration risk: revenue appears heavily tied to the GSK/Flovent authorized-generic franchise, and the 2024 FDA approval of Glenmark's true generic version of Flovent with 180-day market exclusivity directly threatens authorized-generic economics going forward. Leadership is family-controlled, with E. Thomas Arington as founder and chairman and Christopher Arington as vice chairman and CEO. The company does not disclose revenue, has not raised institutional funding, and operates exclusively in the U.S. market with no public listing.

Name

Prasco Laboratories

Legal name

Prasco Laboratories

Website

https://prasco.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

Prasco Laboratories is a privately held U.S. authorized-generic pharmaceutical company that manufactures and distributes therapeutically equivalent versions of branded drugs on behalf of brand owners, primarily serving U.S. pharmacies and healthcare providers with products like the authorized generic of GSK's Flovent.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Authorized generics
• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Drug distribution
• Respiratory medications

Headquarters

HQ city

Mason

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Authorized Generic Pharmaceutical Manufacturing: Prasco manufactures and distributes authorized generic versions of branded pharmaceutical products through partnerships with original drug manufacturers like GSK. Revenue is generated through the sale of these generics to pharmacies and healthcare providers, with pricing typically lower than branded equivalents while maintaining therapeutic equivalence.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Prasco Laboratories manufactures and distributes authorized generic versions of branded pharmaceutical products, operating as a partner to originator drug manufacturers. Its flagship offering is the authorized generic of GSK's Flovent (fluticasone propionate) asthma inhaler, produced under partnership agreements and sold through U.S. pharmacy distribution channels. The company specializes in providing therapeutic equivalents at lower price points while maintaining FDA-compliant manufacturing standards.

Product overview

Prasco Laboratories operates as an authorized generic pharmaceutical company, distributing generic versions of branded medications through partnerships with original manufacturers. The company's primary product offering is the authorized generic version of GSK's Flovent asthma inhaler, which they distribute through their partnership with GSK. They do not appear to offer a unified platform but rather serve as a distribution channel for manufacturer-authorized generic pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

• Authorized Generic Flovent Authorized generic versions of GSK's Flovent (fluticasone propionate) asthma inhaler, manufactured and distributed by Prasco under partnership with GSK following discontinuation of the branded product. Marketed to retail and institutional pharmacies and dispensed to patients with chronic respiratory conditions such as asthma.

Quantifiable outcome

• Expansion of patient access to affordable asthma treatment through authorized generic distribution

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core and flagship.

• Frontier Scientific SolutionscoreStrategic or Co-development Partner · 2 December 2025Prasco Laboratories announced a strategic collaboration with Frontier Scientific Solutions to enhance pharmaceutical supply chain logistics. The partnership leverages Frontier's temperature-controlled logistics capabilities to address industry challenges including damages, theft, and shortages. The alliance aims to ensure product integrity and safety, reflecting the growing importance of specialized logistics in the expanding pharmaceutical market.
• GSKflagshipChannel Partner/ Reseller/ Distributor · 1 January 2024GSK partnered with Prasco Laboratories as an authorized generic partner for its Flovent asthma inhaler products. GSK discontinued its branded versions of Flovent at the start of 2024 and has since sold authorized generic versions through its Ohio-based partner Prasco Laboratories. This partnership allowed GSK to manage market transitions while maintaining patient access to the medication through lower-cost generic alternatives.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Sandoz: Global generic and biosimilar leader that maintains authorized-generic and private-label arrangements with originator companies, overlapping with Prasco's authorized-generic business model. Operates at meaningfully greater scale across therapeutic areas.
• Viatris (Mylan): Large generic pharmaceutical manufacturer with broad respiratory portfolio including generic Advair Diskus and other authorized and traditional generic offerings that overlap with Prasco's therapeutic-area focus and authorized-generic distribution model.
• Teva Pharmaceutical Industries: One of the largest generic pharmaceutical manufacturers globally with significant respiratory franchise (including generic ProAir and Proventil HFA inhalers). Competes with Prasco in respiratory generic inhalers and authorized-generic-type arrangements.
• Mallinckrodt Pharmaceuticals: Specialty/generic pharmaceutical manufacturer with respiratory, allergy, and specialty brands plus generics portfolio, partially overlapping with Prasco's authorized-generic distribution focus in respiratory and specialty therapeutic areas.
• Hikma Pharmaceuticals: Generic and specialty pharmaceutical manufacturer with US respiratory franchise (including generic albuterol sulfate). Operates comparable authorized-generic and traditional generic inhalation-product business serving US healthcare providers.

Direct peers

• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with US distribution and authorized-generic arrangements. Comparable business model as a multi-therapeutic authorized-generic and traditional generic manufacturer serving US pharmacy and institutional channels.
• Glenmark Pharmaceuticals: Direct competitor in the US generic respiratory market. Glenmark received FDA approval for the first true generic version of GSK's Flovent, directly challenging Prasco's authorized generic of the same molecule for the same patient population.
• Amneal Pharmaceuticals: US-focused generic pharmaceutical manufacturer with respiratory franchise (e.g., generic albuterol sulfate inhalation aerosol). Operates similar authorized-generic and traditional generic manufacturing/distribution model targeting overlapping pharmacy channels.
• Lupin Pharmaceuticals: Generic pharmaceutical manufacturer with US respiratory portfolio (including generic albuterol HFA). Competes with Prasco in the same therapeutic category using a similar generic manufacturing and US distribution model to pharmacy customers.

Others

• Organon & Co. Women's health and established brands company that has pursued authorized-generic strategies for lifecycle management of legacy branded assets. Operates in adjacent brand-lifecycle dynamics that drive demand for authorized-generic partners like Prasco.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/prascoags
• Facebookfacebook.com/prascolabs
• LinkedInlinkedin.com/company/prasco

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prasco Laboratories